Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12395195 | 0.88 | PIK3CD (0.33) | MAPTGAATDP1 | |
| SCHEMBL1698568 | 0.82 | — | — | |
| SCHEMBL3075602 | 0.81 | MAPT (0.32) | MAPTGAATDP1 | |
| SCHEMBL22861969 | 0.72 | SMN1; SMN2 (0.33) | GAATDP1 | |
| SCHEMBL14499440 | 0.70 | — | — | |
| SCHEMBL761343 | 0.70 | MAPT (0.33) | MAPTGAATDP1 | |
| SCHEMBL9200910 | 0.69 | — | — | |
| SCHEMBL18650798 | 0.67 | SLC6A2 (0.38) | MAPTGAATDP1 | |
| SCHEMBL20416957 | 0.65 | — | — | |
| SCHEMBL10224081 | 0.65 | MAPT (0.36) | MAPTGAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-8362005-B2 | Monocyclic amide CGRP receptor antagonists | Merk. Sharp & Dohme Corp. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8349873-B2 | Factor XA inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349873-B2 | Factor XA inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120088795-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-20120088795-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-8063077-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110172205-A1 | MONOCYCLIC AMIDE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110118244-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118244-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20100249117-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2010-09-30 | — | — | US | disclosed |
| US-7767697-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-7763608-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20090030045-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20070259924-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2007-11-08 | — | — | US | disclosed |
| US-7235549-B2 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7214677-B2 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. (US) | 2007-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030045-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | MAPT 4551/4885GAA 324/4885TDP1 1622/4885 |
| US-20110118244-A2 | FACTOR XA INHIBITORS | TFPI, F12, F11 | MAPT 4551/4885GAA 324/4885TDP1 1622/4885 |
| US-20100249117-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | MAPT 4551/4885GAA 324/4885TDP1 1622/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | MAPT 89/4885GAA 1897/4885TDP1 139/4885 |
| US-20070259924-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | MAPT 4551/4885GAA 324/4885TDP1 1622/4885 |
| US-20110172205-A1 | MONOCYCLIC AMIDE CGRP RECEPTOR ANTAGONISTS | EDNRB, CCKBR, EDNRA | MAPT 2841/4885GAA 2972/4885TDP1 3269/4885 |
| US-20120088795-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | MAPT 4551/4885GAA 324/4885TDP1 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.